Baricitinib, originally developed for the treatment of RA, inhibits cytokine signaling, including IL-6, IL-12, IL-20, IL-22, IL-23, and IFN-γ, but also exerts regulatory effects on the Th2 cytokines such as IL-4, IL-5, and IL-13.[7] Therefore, it appears to be a candidate drug with the potential to reduce glucocorticoid doses in both RA and CEP. Here, IL4 is linked to rheumatoid arthritis.